Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Plan to develop new products from brewing by-products generated by Asahi Group.
December 1, 2020
By: Contract Pharma
Contract Pharma Staff
Embion Technologies S.A., an industrial biotechnology and green chemistry innovator, and Asahi Group Holdings Ltd. (AGH) and its R&D subsidiary company, Asahi Quality and Innovations Ltd. (AQI) will cooperate to develop and deliver new products by combining each partners’ expertise and know-how. As part of this partnership, Embion has already raised part of the Series A funding round which opened earlier in mid-November, with existing shareholders’ strong expected participation. The parties today announced a partnership which aims at leveraging breakthrough technologies to create new products from brewing by-products generated by Asahi Group, while building a circular economy through sustainable sourcing and production. Leveraging Combined Expertise Embion will provide technology and knowhow to biomass processing and deriving customized, bioactive super-extracts from plant and microbial biomass. Embion’s platform technology accelerates the development of functional nutrition by tapping into and extracting highly potent molecules from industrial biomass side-streams. AQI is the central hub for cutting-edge research in Asahi Group, engaging in research themes and core technologies that may lead to mid-to-long-term developments in Asahi Group. Through these activities, AQI will contribute not only to financial growth of the Asahi Group but also to creation of shared values. “We are very excited about the strategic cooperation with Asahi. By building strategic alliances like this, we can leverage our platform technology globally and continue our growth trajectory which will be supported by our Series A funding round launched in mid-November, ” said Andreas Th. Weckherlin, chairman of the Board at Embion. About the Collaboration The collaboration between the parties was initiated more than two years ago when Embion was developing its first super-extract Prembion for supporting antibiotics-free growing of production animals by upcycling the grain byproduct that is generated through the process of beer making. “The Asahi-Embion partnership brings together deep skills in business and technology strategy, product ideation, technology development and deployment. The potential of our collaboration is as impactful as our technologies,” added Georgios Savoglidis, founder and CEO of Embion. “We highly appreciate Embion’s technology thorough experiments. Through our partnership with Embion we aim to deliver on accelerating the promotion of sustainability on a global basis. Future food and supply security demand the use of localized resources while exploring the most advanced fundamental technologies available,” commented Manabu Sami, president and representative director of AQI. With the conclusion of the JDA, the partners will work on a detailed study of business development by using Embion’s technology. As part of this partnership, Embion and AQI will accelerate the creation of new values by upcycling the brewing by-products, contributing to the realization of a future-proof circular economy.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !